Synaptics Astra™ AI-Native IoT Compute Platform Wins 2024 EDGE Award
SAN JOSE, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) today announced that its Synaptics Astra™ AI-native […]
Robinhood Crypto Launches Crypto Transfers in Europe
Robinhood Crypto customers in Europe can now deposit and withdraw 20+ cryptocurrencies, and will earn a 1% deposit match for […]
Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event
Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage […]
WISeKey’s Extensive Expertise Lays the Foundation for the Development of a Semiconductor Manufacturing Project in Switzerland
WISeKey’s Extensive Expertise Lays the Foundation for the Development of a Semiconductor Manufacturing Project in Switzerland Geneva, Switzerland – October […]
Li Auto Inc. September 2024 Delivery Update
BEIJING, China, Oct. 01, 2024 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), […]
Eagle Bancorp, Inc. Positions for Growth Through Capital Actions
BETHESDA, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) — Eagle Bancorp, Inc. (NASDAQ: EGBN), the Bethesda-based holding company for EagleBank, one […]
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing […]
HomesToLife Ltd Announces Pricing of Initial Public Offering
SINGAPORE, Sept. 30, 2024 (GLOBE NEWSWIRE) — HomesToLife Ltd. (“HTLM” or the “Company”) today announced the pricing of its initial […]
Edible Garden Announces Closing of $5.65 Million Public Offering
BELVIDERE, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), […]
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable […]
